癌症研究
乳腺癌
基因敲除
GPX4
生物
激酶
程序性细胞死亡
厌氧糖酵解
癌症
糖酵解
癌细胞
细胞凋亡
重编程
巴基斯坦卢比
医学
内科学
脂质代谢
细胞
蛋白激酶A
细胞生物学
基因沉默
平衡
三阴性乳腺癌
作者
Felix Oyelami,Andrew T. Shinkle,Chrispus Mutuku Ngule,Folake A. Oyelami,Oluwafunminiyi E. Obaleye,Amos Olalekan Akinyemi,Tijesunimi Tomisin Oyetunde,Samuel O. Nwadialo,Xiongjian Rao,Xingcong Ren,Jinming Yang
出处
期刊:
[University of Kansas]
日期:2026-04-17
卷期号:3 (2)
标识
DOI:10.17161/sjm.v3i2.25240
摘要
Therapeutic resistance and recurrence are primary contributors to poor outcomes in breast cancer patients. Induction of ferroptosis, a type of cell death characterized by overload of toxic lipid peroxides has appreciated as a viable strategy in treatment of breast cancers including lethal subtypes such as triple-negative breast cancer (TNBC). Notwithstanding, some cancer subtypes are resistant to ferroptosis and the underlying mechanisms remain incompletely understood. The current study shows that phosphoglycerate kinase 1 (PGK1), a glycolysis-regulating enzyme, is highly expressed in advanced tumor stages, and correlates with ferroptosis resistance as well as poor outcomes, especially in TNBCS. Using genetic and pharmacological approaches, we demonstrated that PGK1 depletion attenuates ferroptosis resistance in TNBC and luminal breast cancer cell lines. We also showed that PGK1 depletion destabilizes GPX4, an anti-ferroptosis defense peroxidase in parallel with pyruvate dehydrogenase (PDH) to disrupt redox homeostasis and enhance lipid peroxidation. In orthotopic TNBC models, we showed that tumoral loss of PGK1 enhances activity of the ferroptosis inducer imidazole ketone erastin (IKE) and reduces tumor size and metastasis. These results indicate that PGK1 plays a key role in modulating breast cancer sensitivity to ferroptosis induction, suggesting that this kinase may be exploited as a therapeutic target to overcome resistance to ferroptosis inducers in breast cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI